However, after adjusting for whether they had Crohn's disease or ulcerative colitis, as well as other factors such as gender and age, African Americans had a lower chance (about 12 percent lower) of getting infliximab treatment compared to Caucasian patients with IBD. Analyses limited to the 73,109 patients with moderate-to-severe disease revealed similar findings???about a 15 percent lower chance